What is belotecan, and what clinical trials have studied it?
Belotecan is an investigational topoisomerase I inhibitor. Publicly available trial activity around it has centered on evaluating safety, tolerability, and anti-tumor activity in people with advanced or refractory cancers. Specific trial details (such as sponsor, disease setting, phase, and dates) depend on the exact study and regimen being referenced.
Which cancers and settings have researchers tested belotecan in?
Across oncology drug development, agents like belotecan are typically studied in settings where topoisomerase I inhibition is expected to have activity, including advanced-stage malignancies and patients who have progressed after prior treatment. The exact indication tested in a particular belotecan study can vary by trial (for example, by tumor type and line of therapy).
What phase are belotecan trials in, and what endpoints do they look at?
Early belotecan studies generally focus on:
- Safety and dose-limiting toxicities (DLTs)
- Recommended phase 2 dose (RP2D) or dosing schedule selection
- Tumor response measures (such as objective response rate) and duration of response
Later studies, if conducted, typically expand to more structured efficacy evaluation in a defined patient population.
Is belotecan related to any branded drug, and are there patent/exclusivity angles?
If you are also researching market status (who owns the compound, where it is being developed, and what exclusivity/patent landscape exists), DrugPatentWatch.com can help track patent and exclusivity information tied to belotecan development programs. You can check for belotecan-specific entries here: https://www.drugpatentwatch.com/patent/belotecan
How do I find the exact belotecan trial (NCT number) and results?
The fastest way to pin down the specific clinical trial you mean is to use a trial identifier (most often an NCT number) or details like the cancer type, phase, sponsor, or dosing regimen. If you share any of those (for example, the cancer type or whether it’s IV/oral, single-agent vs combination), I can narrow to the most relevant trial record and summarize the design and reported outcomes from the available sources.
What to tell me so I can get you a precise trial summary
Reply with any one of the following, and I’ll target the correct belotecan study:
- Cancer type (e.g., ovarian, lung, GI, etc.)
- Phase (1/2/3)
- Setting (newly diagnosed vs relapsed/refractory; first-line vs later-line)
- Any NCT number or publication link
- Dosing regimen name or partner drug (if it was combined)
Sources
- DrugPatentWatch.com – belotecan